Urology

FDA Panel: Approve Mirabegron for Overactive Bladder

Publish date: April 5, 2012

Publish date: February 16, 2012

Major Finding: Men given vitamin E supplements had a 17% relative increase in the risk of prostate cancer compared with men given placebo; however...

Publish date: February 13, 2012

Major Finding: Everolimus was superior to placebo in terms of achieving an angiomyolipoma response (41.8% vs. 0%; P less than .0001) and the time...

Publish date: January 6, 2012

Major Finding: After 13 years of follow-up, cumulative mortality from prostate cancer was not significantly different in men randomized to either...

Publish date: October 7, 2011

Major Finding: PSA screening for prostate cancer failed to significantly reduce long-term prostate cancer-specific mortality in multiple studies (...

Publish date: October 6, 2011